Virtual screening and optimization of Type II inhibitors of JAK2 from a natural product library.

Amentoflavone has been identified as a JAK2 inhibitor by structure-based virtual screening of a natural product library. In silico optimization using the DOLPHIN model yielded analogues with enhanced potency against JAK2 activity and HCV activity in cellulo. Molecular modeling and kinetic experiments suggested that the analogues may function as Type II inhibitors of JAK2.

[1]  Hui Yang,et al.  Structure-based optimization of FDA-approved drug methylene blue as a c-myc G-quadruplex DNA stabilizer. , 2011, Biochimie.

[2]  W. Marsden.  I and J , 2012 .

[3]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[4]  J. Rossjohn,et al.  The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. , 2006, Blood.

[5]  Dik-Lung Ma,et al.  Hit identification of IKKβ natural product inhibitor , 2013, BMC Pharmacology and Toxicology.

[6]  L. Tong,et al.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.

[7]  Fang Yang,et al.  Identification of natural product fonsecin B as a stabilizing ligand of c-myc G-quadruplex DNA by high-throughput virtual screening. , 2010, Chemical communications.

[8]  Dik-Lung Ma,et al.  Drug repositioning by structure-based virtual screening. , 2013, Chemical Society reviews.

[9]  R. Abagyan,et al.  Structure-based discovery of natural-product-like TNF-α inhibitors. , 2010, Angewandte Chemie.

[10]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[11]  D. Chan,et al.  Molecular modeling of drug-DNA interactions: virtual screening to structure-based design. , 2011, Biochimie.

[12]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[13]  A. Siddiqui,et al.  Hepatitis C Virus (HCV) Constitutively Activates STAT-3 via Oxidative Stress: Role of STAT-3 in HCV Replication , 2005, Journal of Virology.

[14]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[15]  Takeshi Tokuhisa,et al.  Activation of STAT3 by the Hepatitis C Virus Core Protein Leads to Cellular Transformation , 2002, The Journal of experimental medicine.

[16]  D. Chan,et al.  In silico identification of natural product inhibitors of JAK2. , 2015, Methods.

[17]  W. Sellers,et al.  Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. , 2012, Cancer discovery.

[18]  D. Chan,et al.  Structure-based repurposing of FDA-approved drugs as inhibitors of NEDD8-activating enzyme. , 2014, Biochimie.

[19]  J. O’Shea,et al.  Janus kinases in immune cell signaling , 2009, Immunological reviews.

[20]  Dik-Lung Ma,et al.  Molecular docking for virtual screening of natural product databases , 2011 .

[21]  Dik-Lung Ma,et al.  Discovery of a natural product inhibitor targeting protein neddylation by structure-based virtual screening. , 2012, Biochimie.

[22]  Ruben Abagyan,et al.  A natural product-like inhibitor of NEDD8-activating enzyme. , 2011, Chemical communications.

[23]  R. Geney,et al.  Type II kinase inhibitors: an opportunity in cancer for rational design. , 2013, Anti-cancer agents in medicinal chemistry.

[24]  R. Abagyan,et al.  Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. , 2008, Journal of medicinal chemistry.

[25]  Dik-Lung Ma,et al.  In silico screening of quadruplex-binding ligands. , 2012, Methods.

[26]  N. Hayashi,et al.  Hepatitis C Virus Core Protein Differently Regulates the JAK-STAT Signaling Pathway under Interleukin-6 and Interferon-γ Stimuli* , 2003, Journal of Biological Chemistry.